Content by Lonza

The expanded partnership reflects strong demand for Lonza’s global biologics outsourcing platform, spanning diversified clinical and commercial manufacturing programs.

The agreement covers clinical supply of bimiralisib, supporting Torqur AG’s phase 2 program in actinic keratosis and broader oncology development.

ImmuneOncia selects Lonza to manufacture late-stage clinical supply of its PD-L1 antibody Danburstotug for relapsed/refractory NK/T-cell lymphoma.

Explore how advanced in vitro and in vivo model systems combined with high-throughput CRISPR screening improve translational confidence.

Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 

Lonza strengthens its pharmaceutical quality control portfolio through the acquisition of Redberry, enabling faster and more reliable microbial testing.

Discover how coculture models and CRISPR tools reveal new insights into tumour microenvironments.

Explore how combining human immune and epithelial or cancer cells in vitro enhances predictive power in infectious disease and oncology research.

Join two days of expert-led discussions exploring the tools, targets, and translational strategies driving innovation in oncology drug development.

As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?

Explore the applications of CRISPR-Cas9 technology in therapeutic development for Alzheimer’s disease.

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.